791 results on '"Bégaud, Bernard"'
Search Results
2. Quelles actions pour lutter contre la désinformation sur les produits de santé ?
3. What should be done to combat misinformation about health products?
4. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis
5. Drugs and the elderly: A complex interaction
6. Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study
7. Using Discretely Integrated Condition Event Simulation To Construct Quantitative Benefit–Risk Models: The Example of Rotavirus Vaccination in France
8. Patterns of Benzodiazepine Use and Excess Risk of All-Cause Mortality in the Elderly: A Nationwide Cohort Study
9. Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
10. Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines
11. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus
12. Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure
13. A history of pharmacoepidemiology
14. What should be done to combat misinformation about health products?*
15. Human papillomavirus vaccine and demyelinating diseases—A systematic review and meta-analysis
16. Pharmacoepidemiology and public decision
17. Methods for the Post-Marketing Monitoring of Psychotropics Safety: Interests and Pitfalls
18. Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database
19. Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users
20. An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study
21. Usage et mésusage des médicaments psychotropes : les antipsychotiques, nouvelle panacée pour les troubles psychiatriques ?
22. Benzodiazepine, psychotropic medication, and dementia: A population-based cohort study
23. Causality assessment in pharmacovigilance: The French method and its successive updates
24. Imputabilité en pharmacovigilance : de la méthode française originelle aux méthodes réactualisées
25. Utilization of psychotropic drugs by patients consulting for sleeping disorders in homeopathic and conventional primary care settings: the EPI3 cohort study
26. Impact of pioglitazone regulatory withdrawal on antidiabetic drug use and health in diabetic patients
27. Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database
28. Incidence of Agranulocytosis in Southwest France
29. Characteristics of patients consulting their regular primary care physician according to their prescribing preferences for homeopathy and complementary medicine
30. Benzodiazepine use and risk of Alzheimer’s disease : case-control study
31. Vaccine Case–Population: A New Method for Vaccine Safety Surveillance
32. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase®
33. Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users
34. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases
35. The Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
36. Relative Risks from Case-Population Data
37. Trends in the incidence of use of noninsulin glucose‐lowering drugs between 2006 and 2013 in France
38. A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products
39. Assessing drug causality: It is time to become European!
40. An original pharmacoepidemiological–pharmacodynamic method: application to antipsychotic‐induced movement disorders
41. Trends in incident use of benzodiazepines and Z‐drugs in France from 2006 to 2012: a population‐based study
42. Authors' reply
43. An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance
44. Benzodiazepine use and risk of dementia: population based study
45. How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system
46. Authors’ Reply to Cohen et al.’s Comment on “Central Demyelinating Diseases after Vaccination Against Hepatitis B Virus: A Disproportionality Analysis within the VAERS Database”
47. Improving pharmacovigilance in Europe
48. Impact of Prescriber Nonresponse on Patient Representativeness
49. Alzheimer disease: Leave no stone unturned
50. Fibrates and Risk of Cancer in Tissues with High PPAR-α Concentration: A Nested Case–Control Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.